Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis

Human Gene Therapy Clinical Development

Volumn 28, Issue 2, 2017, Pages 68-73

  Zabaleta, Nerea ^a   Salas, David ^a   Paramo, Maria ^b   Hommel, Mirja ^a   Sier Ferreira, Valerie ^c   Hernandez Alcoceba, Ruben ^a   Prieto, Jesus ^a   Bilbao, Jose I ^b   Gonzalez Aseguinolaza, Gloria ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIQURE   (Netherlands)

Author keywords

Adeno associated virus; clinical development; delivery methods; disease models; IND enabling studies; liver; metabolic; vectors

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BALLOON CATHETER; BALLOON OCCLUSION; ENZYME BLOOD LEVEL; GENE EXPRESSION; HEPATIC ARTERY; INTERVENTIONAL RADIOLOGY; LIVER; LIVER BLOOD FLOW; LIVER TISSUE; LIVER VEIN; MACACA FASCICULARIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS SHEDDING; ADMINISTRATION AND DOSAGE; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PROCEDURES; VASCULARIZATION;

ALKALINE PHOSPHATASE; ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; LIVER; MACACA FASCICULARIS; PROMOTER REGIONS, GENETIC; TRANSDUCTION, GENETIC;

EID: 85020820351     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2016.183     Document Type: Article

References (21)

1. World Health Organization. Genomic Research Centre: genes and human disease. 2017. Available at: http://www.who.int/genomics/public/geneticdiseases/en/index2.html [accessed March 12, 2017].
2. Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 2014;15:445-451.
3. Lisowski L, Tay SS, Alexander IE. Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol 2015;24:59-67.
4. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011;12:341-355.
5. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-348.
6. Paneda A, Lopez-Franco E, Kaeppel C, et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther 2013; 24:1007-1017.
7. D'Avola D, López-Franco E, Sangro B, et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol 2016; 65:776-783.
8. Murillo O, Moreno-Luqui D, Gazquez C, et al. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. J Hepatol 2016;64: 419-426.
9. Salido E, Rodriguez-Pena M, Santana A, et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther 2011;19:870-875.
10. Fagiuoli S, Daina E, D'Antiga L, et al. Monogenic diseases that can be cured by liver transplantation. J Hepatol 2013;59:595-612.
11. Mao Y, Wang X, Yan R, et al. Single point mu-tation in adeno-associated viral vectors: DJ capsid leads to improvement for gene delivery in vivo. BMC Biotechnol 2016;16:1-8.
12. Crettaz J, Berraondo P, Mauleón I, et al. In-trahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology 2006;44:623-632.
13. Mimuro J, Mizukami H, Hishikawa S, et al. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther 2013;21:318-323.
14. Brunetti-Pierri N, Ng T, Iannitti DA, et al. Im-proved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent ade-noviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther 2006;17: 391-404.
15. Brunetti-Pierri N, Stapleton GE, Palmer DJ, et al. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 2007;15: 732-740.
16. Brunetti-Pierri N, Stapleton GE, Law M, et al. Efficient, Long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 2009;17:327-333.
17. Brunetti-Pierri N, Ng T, Iannitti D, et al. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum Gene Ther 2013;24: 761-765.
18. Brunetti-Pierri N, Palmer DJ, Mane V, et al. Increased Hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther 2005;12:99-106.
19. Liu F, Song Y, Liu D. Hydrodynamics-based trans-fection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-1266.
20. Oka K, Mullins CE, Kushwaha RS, et al. Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector. Gene Ther 2014;22:87-95.
21. Dane AP, Wowro SJ, Cunningham SC, et al. Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther 2013;20:460-464.